Company: PTPI
Filing Date: 2025-01-24
Form Type: S-1
Source: 0001410578-25-000047
Chunk: 209

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-01-24
Form: S-1
Chunk 209
---
 No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (ASU 2023-07), which requires an enhanced disclosure of significant segment expenses on an annual and interim basis. This guidance will be effective for the annual periods beginning the year ended December 31, 2024, and for interim periods beginning January 1, 2025. Early adoption is permitted. Upon adoption, the guidance should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating segment expense disclosures related to its annual report for fiscal year 2024. In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09), which improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the effective tax rate reconciliation and income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. This guidance will be effective for the annual periods beginning the year ended December 31, 2025. Early adoption is permitted. Upon adoption, the guidance can be applied prospectively or retrospectively. The Company is currently evaluating income tax disclosures related to its annual report for fiscal year 2025.

3) Accounts Receivable, net

Accounts receivable, net is comprised of the following:

| ​                               
 ​                               | ​ 
 ​ 
 ​ | ​    
 2023 |            ​ 
 December 31, | ​ 
 ​ | ​    
 2022 |            ​ 
 December 31, |
|:--------------------------------|:--|:-----|-------------:|:--|:-----|-------------:|
| Gross accounts receivables      | ​ | $    |    2,887,317 | ​ | $    |    2,757,839 |
| Distribution service fees       |   | ​    |     -398,968 |   | ​    |     -339,094 |
| Chargebacks accrual             |   | ​    |       -2,462 |   | ​    |       -1,960 |
| Cash discount allowances        |   | ​    |      -24,639 |   | ​    |      -99,671 |
| Allowance for doubtful accounts |   | ​    |     -235,097 |   | ​    |     -206,868 |